Financial Position - As of June 30, 2023, total assets amounted to HKD 2,829,122,000, an increase from HKD 2,712,397,000 as of December 31, 2022, representing a growth of approximately 4.3%[1] - Current assets increased to HKD 1,337,241,000 from HKD 1,213,978,000, reflecting a rise of about 10.2%[1] - The net value of current assets reached HKD 712,207,000, up from HKD 653,061,000, indicating an increase of approximately 9.0%[3] - Total liabilities rose to HKD 1,021,071,000 from HKD 981,030,000, marking an increase of about 4.1%[3] - Non-current liabilities decreased to HKD 396,037,000 from HKD 420,113,000, showing a reduction of approximately 5.7%[3] - The company's equity increased to HKD 1,808,051,000 from HKD 1,731,367,000, representing a growth of about 4.4%[3] Revenue and Profitability - The company reported a total comprehensive income of HKD 46,030,000 for the period, down from HKD 139,231,000, indicating a decrease of approximately 66.9%[5] - Total revenue from the ophthalmology segment was HKD 381,569 thousand, while the surgical segment generated HKD 517,790 thousand, leading to a total revenue of HKD 899,359 thousand for the six months ended June 30, 2023, compared to HKD 655,825 thousand in the same period of 2022, indicating an increase of approximately 37.1%[18] - Profit before tax for the six months ended June 30, 2023, was HKD 204,855,000, up from HKD 162,701,000 in the same period of 2022[20] - Profit for the period increased by 22.0% to approximately HKD 169.8 million, up from approximately HKD 139.2 million in the previous year[147] Cash Flow and Investments - The company reported a net cash inflow from operating activities of HKD 155,006 thousand for the six months ended June 30, 2023, compared to HKD 230,392 thousand for the same period in 2022, representing a decrease of approximately 32.6%[7] - The net cash used in investing activities was HKD 106,799 thousand for the six months ended June 30, 2023, a decrease from HKD 143,617 thousand in the same period of 2022, indicating a reduction of approximately 25.6%[9] - The company’s financing activities resulted in a net cash outflow of HKD 71,619 thousand for the six months ended June 30, 2023, compared to HKD 94,588 thousand in the same period of 2022, showing a decrease of approximately 24.2%[9] Assets and Liabilities - The company reported a total cash and cash equivalents balance of HKD 505,722 thousand as of June 30, 2023, down from HKD 641,136 thousand at the end of the previous year, representing a decrease of approximately 21.1%[9] - The company’s total liabilities decreased from HKD 671,336 thousand at the beginning of the period to HKD 543,486 thousand by the end of the period, indicating a reduction of approximately 19.1%[9] - As of June 30, 2023, the total property, plant, and equipment amounted to HKD 510,434,000, a decrease from HKD 531,570,000 as of December 31, 2022[42] Shareholder Information - The group declared an interim dividend of HKD 0.045 per share for the six months ended June 30, 2023, compared to HKD 0.04 per share in the same period of 2022[36] - Basic earnings attributable to shareholders for the six months ended June 30, 2023, were HKD 169,811,000, an increase from HKD 139,231,000 in the same period of 2022[38] - The average number of ordinary shares used for calculating basic earnings per share was 571,307,122 for the six months ended June 30, 2023[39] Research and Development - The group has six commercialized biopharmaceutical products in China, which are part of the bFGF series[113] - The group is engaged in multiple clinical projects at different stages of development, focusing on single-dose ophthalmic products and biologics[116] - The total investment cost for the clinical development of the SkQ1 product is approximately HKD 348,000,000, representing 12.3% of the company's total assets as of June 30, 2023[127] Market and Sales - The group reported a total revenue contribution of approximately 87.6% from the bFGF series during the review period[113] - The flagship biopharmaceutical products, Beifu Shu series and Beifu Ji series, accounted for 87.6% of total revenue, with contributions of 31.9% and 55.7% respectively[148] - The estimated number of moderate to severe dry eye patients in China was approximately 119,700,000 in 2020, indicating a significant potential market size for the SkQ1 product[127] Employee and Compensation - As of June 30, 2023, the group had a total of 1,462 full-time employees, a slight decrease from 1,471 employees as of December 31, 2022[184] - Total employee compensation for the period was approximately HKD 173 million, compared to approximately HKD 161.2 million in the previous period[184] Financing and Debt - The company has secured bank financing of approximately HKD 475,400,000, with about HKD 475,100,000 already utilized[175] - The convertible loan payable to the International Finance Corporation amounts to HKD 150,000,000, with an annual interest rate of 1.9%[85][86] - The company voluntarily repaid the entire loan prior to the repayment plan on July 17, 2023[173]
亿胜生物科技(01061) - 2023 - 中期业绩